(NASDAQ: XERS) Xeris Biopharma Holdings's forecast annual revenue growth rate of 18.81% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 103.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.
Xeris Biopharma Holdings's revenue in 2025 is $266,137,000.On average, 8 Wall Street analysts forecast XERS's revenue for 2025 to be $48,644,023,806, with the lowest XERS revenue forecast at $46,342,653,918, and the highest XERS revenue forecast at $50,280,037,296. On average, 8 Wall Street analysts forecast XERS's revenue for 2026 to be $62,200,038,217, with the lowest XERS revenue forecast at $54,944,169,059, and the highest XERS revenue forecast at $75,316,353,263.
In 2027, XERS is forecast to generate $73,715,183,874 in revenue, with the lowest revenue forecast at $63,464,381,300 and the highest revenue forecast at $87,302,723,900.